FAAP100

FAAP100 is an essential structural and catalytic component of the Fanconi anemia (FA) core complex, the multisubunit E3 ubiquitin ligase that monoubiquitinates the FANCD2-FANCI heterodimer to activate DNA interstrand crosslink (ICL) repair (PMID:17396147, PMID:24910428). FAAP100 directly associates with FANCB and FANCL to form the minimal catalytic trimer (the BLP100 monoubiquitination module) that is sufficient to monoubiquitinate FANCD2 in vitro and is absolutely required for E3 ligase function, whereas ancillary modules (FANCA-FANCG-FAAP20 and FANCC-FANCE-FANCF) are dispensable for residual activity (PMID:24905007, PMID:24910428, PMID:27986371). Structurally, FANCB and FAAP100 form two central dimers that flank and dimerize two copies of FANCL, building a dimer-of-trimers scaffold that symmetrically positions both FANCL molecules to monoubiquitinate the DNA-bound FANCD2-FANCI heterodimer; despite lacking sequence homology, FANCB and FAAP100 adopt similar folds, and destabilizing this scaffold collapses the entire complex (PMID:27986592, PMID:31666700). FAAP100 is required for FANCL stability and for nuclear translocation and chromatin recruitment, and its incorporation into the BLP100 subcomplex is itself the prerequisite for its own nuclear import (PMID:17396147, PMID:40232843). Loss of FAAP100 abolishes FANCD2/FANCI monoubiquitination, causes ICL hypersensitivity and genomic instability (PMID:17396147), and in mouse primordial germ cells disrupts R-loop resolution and replication fork protection, driving transcription-replication conflicts and p53-dependent proliferation defects (PMID:37580696). Germline loss-of-function variants in FAAP100 cause a severe form of Fanconi anemia designated FANCX, with patient cells showing defective monoubiquitination and ICL hypersensitivity rescued by wild-type but not variant cDNA (PMID:40232843, PMID:40244696).

1. 2007 High

   Established that FAAP100 is a bona fide FA core complex component by showing it directly binds FANCB and FANCL and is required for FANCD2 monoubiquitination, defining its place in the ICL repair pathway.

   Evidence Co-IP, siRNA depletion and knockout with FANCD2 monoubiquitination, crosslink sensitivity, and nuclear localization readouts

   PMID:17396147

   Open questions at the time

   • Did not resolve whether the FANCB-FANCL-FAAP100 trimer is catalytically sufficient on its own
   • No structural basis for the interactions
2. 2014 High

   Defined the FANCB-FANCL-FAAP100 trimer as the minimal catalytic monoubiquitination module sufficient for FANCD2 modification and showed ancillary modules are not required for activity, isolating the catalytic core.

   Evidence In vitro reconstitution with purified native avian FA core complex plus genetic epistasis in subunit-deficient cells (two parallel studies)

   PMID:24905007 PMID:24910428

   Open questions at the time

   • Stoichiometry and architecture of the trimer within the full complex not resolved
   • Mechanism of substrate engagement not defined
3. 2016 High

   Revealed that FANCB and FAAP100 dimerize two FANCL molecules into a dimer-of-trimers poised for symmetric monoubiquitination, and that DNA-bound FANCD2-FANCI is the restricted substrate, explaining the architecture underlying catalysis.

   Evidence EM/XL-MS with in vitro ubiquitination, plus fully recombinant complex reconstitution with substrate-specificity and DNA-dependency assays (two parallel studies)

   PMID:27986371 PMID:27986592

   Open questions at the time

   • Atomic-resolution fold of FAAP100 not yet determined
   • Functional asymmetry between the two FANCL copies unexplained
4. 2019 High

   Provided a high-resolution scaffold model in which FANCB-FAAP100 central dimers organize the entire complex and showed FAAP100 adopts a FANCB-like fold despite no sequence homology, establishing FAAP100 as a structural keystone.

   Evidence Cryo-EM of reconstituted active complex with MS validation

   PMID:31666700

   Open questions at the time

   • Conformational dynamics of the two distinct FANCL states not mechanistically dissected
   • Does not address in vivo regulation of complex assembly
5. 2023 Medium

   Extended FAAP100 function to an in vivo physiological role, showing it counteracts transcription-replication conflicts via R-loop resolution and fork protection during germ cell development.

   Evidence FAAP100 conditional knockout mice with R-loop detection, fork protection assays, p53 pathway analysis, and fertility phenotyping

   PMID:37580696

   Open questions at the time

   • No rescue experiment described
   • Single lab
   • Whether R-loop phenotype is direct or secondary to loss of FANCD2 ubiquitination not separated
6. 2025 High

   Identified FAAP100 as a human Fanconi anemia gene (FANCX) and mechanistically tied disease variants to failure of BLP100 subcomplex assembly, linking subcomplex formation to FAAP100 nuclear import and chromatin recruitment.

   Evidence Patient-derived cell complementation with WT vs. variant cDNA, engineered multi-organism cell models, ICL sensitivity, T542P functional characterization, and mouse knockout (two parallel studies)

   PMID:40232843 PMID:40244696

   Open questions at the time

   • Full spectrum of pathogenic variants not catalogued
   • Genotype-phenotype correlations across patients not established

• How FAAP100-dependent conformational asymmetry between the two FANCL copies is functionally exploited, and how nuclear import of the BLP100 subcomplex is regulated, remain unresolved.
• No mechanism for the distinct roles of the two FANCL conformations
• Regulation of subcomplex-coupled nuclear import not defined